DK1334174T3 - Paramyxovirusvektor til genoverförsel til det cardiovaskulære system - Google Patents

Paramyxovirusvektor til genoverförsel til det cardiovaskulære system

Info

Publication number
DK1334174T3
DK1334174T3 DK01981031T DK01981031T DK1334174T3 DK 1334174 T3 DK1334174 T3 DK 1334174T3 DK 01981031 T DK01981031 T DK 01981031T DK 01981031 T DK01981031 T DK 01981031T DK 1334174 T3 DK1334174 T3 DK 1334174T3
Authority
DK
Denmark
Prior art keywords
cardiovascular system
vector
gene transfer
paramyxovirus vector
paramyxovirus
Prior art date
Application number
DK01981031T
Other languages
English (en)
Inventor
Mamoru Hasegawa
Uta Griesenbach
Stefano Ferrari
Duncan M Geddes
Eric Wfw Alton
Xiaogang Hou
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Application granted granted Critical
Publication of DK1334174T3 publication Critical patent/DK1334174T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01981031T 2000-11-08 2001-11-08 Paramyxovirusvektor til genoverförsel til det cardiovaskulære system DK1334174T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000339942A JP2002142770A (ja) 2000-11-08 2000-11-08 循環系への遺伝子送達用パラミクソウイルスベクター

Publications (1)

Publication Number Publication Date
DK1334174T3 true DK1334174T3 (da) 2006-06-26

Family

ID=18814933

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01981031T DK1334174T3 (da) 2000-11-08 2001-11-08 Paramyxovirusvektor til genoverförsel til det cardiovaskulære system

Country Status (12)

Country Link
US (1) US20040101965A1 (da)
EP (2) EP1662003A3 (da)
JP (1) JP2002142770A (da)
KR (1) KR100852078B1 (da)
CN (1) CN1555417B (da)
AT (1) ATE323149T1 (da)
AU (1) AU2002212733A1 (da)
CA (1) CA2428073C (da)
DE (1) DE60118771T2 (da)
DK (1) DK1334174T3 (da)
ES (1) ES2260301T3 (da)
WO (1) WO2002038726A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
EP1211318B1 (en) 1999-09-06 2007-08-08 DNAVEC Research, Inc. Paramyxoviruses comprising a modified transcription start sequence
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
JPWO2001072340A1 (ja) 2000-03-30 2004-01-08 株式会社ディナベック研究所 センダイウイルスベクターを用いたａｉｄｓウイルスワクチン
AU2001262684A1 (en) * 2000-06-01 2001-12-11 Dnavec Research Inc. Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
WO2002000264A1 (en) * 2000-06-27 2002-01-03 Dnavec Research Inc. Virus vector for transferring gene into renal cells
KR20030042003A (ko) * 2000-10-06 2003-05-27 가부시키가이샤 디나벡크 겐큐쇼 골격근에 외래유전자를 도입하기 위한 파라믹소바이러스 벡터
AU2002224113A1 (en) * 2000-11-27 2002-06-03 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and utilization thereof
CA2484287A1 (en) * 2002-04-30 2003-11-13 Dnavec Research Inc. Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity
JPWO2004022731A1 (ja) * 2002-09-04 2005-12-22 株式会社ディナベック研究所 シアル酸結合活性を有する膜蛋白質をエンベロープに含むウイルスベクターをグラム陽性菌由来ノイラミニダーゼを用いて製造する方法
CA2503317A1 (en) * 2002-10-24 2004-05-06 Dnavec Research Inc. Method of transferring gene into t cells
KR20060028432A (ko) * 2003-06-30 2006-03-29 가부시키가이샤 디나벡크 겐큐쇼 고변이영역이 개변된 유전자를 탑재하는 마이너스가닥 ｒｎａ 바이러스 벡터
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
JPWO2005071085A1 (ja) * 2004-01-22 2007-09-06 株式会社ディナベック研究所 ウイルスベクターの製造方法
US20080038234A1 (en) * 2004-03-23 2008-02-14 Shuji Hayashi Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair
AU2006237903A1 (en) * 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease
WO2006134917A1 (ja) * 2005-06-14 2006-12-21 Dnavec Corporation 抗体の作製方法
DK1950307T3 (da) * 2005-10-28 2016-02-15 Id Pharma Co Ltd Genoverførsel til luftvejsepitelstamcelle ved anvendelse af en lentivirusvektor, som er pseudo-typificeret med RNA-virus-spike-protein
CA2636600A1 (en) * 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147186A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6562596B1 (en) * 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
PT702085E (pt) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
DK0864645T3 (da) * 1995-10-31 2005-10-24 Dnavec Research Inc Negativstrenget RNA-virusvektor med autonom replikeringsaktivitet
DK0863202T3 (da) * 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
EP0884383A4 (en) 1996-02-29 2001-12-05 Takara Shuzo Co METHOD FOR CLEANING AND REMOVING VIRUSES.
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6743620B1 (en) * 1996-12-16 2004-06-01 Eisai Co., Ltd. Method for preparing retrovirus vector for gene therapy
CA2205076A1 (en) * 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
DE69933528T2 (de) * 1998-11-09 2007-08-09 Nippon Biologicals, Inc. Verfahren zur Cytokinproduktionn unter Verwendung eines Sendai Virus Expressionssystems
JP2000201689A (ja) * 1998-11-09 2000-07-25 Nippon Bio Capital Limited:Kk センダイウイルス発現系を用いたサイトカインの製造方法
JP2000253876A (ja) * 1999-03-08 2000-09-19 Dnavec Research Inc センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
ATE399206T1 (de) 1999-05-18 2008-07-15 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
KR100739938B1 (ko) 1999-05-18 2007-07-16 가부시키가이샤 디나벡크 겐큐쇼 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
EP1211318B1 (en) 1999-09-06 2007-08-08 DNAVEC Research, Inc. Paramyxoviruses comprising a modified transcription start sequence
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
HK1047959A1 (en) * 2000-01-19 2003-03-14 Dnavec Research Inc. Use of paramyxovirus vector in gene transfer into blood vessel
JPWO2001072340A1 (ja) * 2000-03-30 2004-01-08 株式会社ディナベック研究所 センダイウイルスベクターを用いたａｉｄｓウイルスワクチン
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
AU2001262684A1 (en) * 2000-06-01 2001-12-11 Dnavec Research Inc. Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
WO2002000264A1 (en) * 2000-06-27 2002-01-03 Dnavec Research Inc. Virus vector for transferring gene into renal cells
KR20030042003A (ko) * 2000-10-06 2003-05-27 가부시키가이샤 디나벡크 겐큐쇼 골격근에 외래유전자를 도입하기 위한 파라믹소바이러스 벡터
AU2002224113A1 (en) * 2000-11-27 2002-06-03 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and utilization thereof
CA2503317A1 (en) * 2002-10-24 2004-05-06 Dnavec Research Inc. Method of transferring gene into t cells
CN1768145A (zh) * 2003-01-31 2006-05-03 株式会社载体研究所 编码核酶的副粘病毒载体及其应用
KR20060028432A (ko) * 2003-06-30 2006-03-29 가부시키가이샤 디나벡크 겐큐쇼 고변이영역이 개변된 유전자를 탑재하는 마이너스가닥 ｒｎａ 바이러스 벡터
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
US20080038234A1 (en) * 2004-03-23 2008-02-14 Shuji Hayashi Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair
AU2006237903A1 (en) * 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease

Also Published As

Publication number Publication date
WO2002038726A2 (en) 2002-05-16
US20040101965A1 (en) 2004-05-27
ES2260301T3 (es) 2006-11-01
DE60118771D1 (de) 2006-05-24
HK1070100A1 (zh) 2005-06-10
EP1334174A2 (en) 2003-08-13
KR20030074617A (ko) 2003-09-19
JP2002142770A (ja) 2002-05-21
CN1555417B (zh) 2010-04-28
AU2002212733A1 (en) 2002-05-21
KR100852078B1 (ko) 2008-08-13
CA2428073A1 (en) 2002-05-16
DE60118771T2 (de) 2007-04-12
EP1662003A2 (en) 2006-05-31
CA2428073C (en) 2012-01-10
WO2002038726A3 (en) 2003-03-20
EP1334174B1 (en) 2006-04-12
CN1555417A (zh) 2004-12-15
ATE323149T1 (de) 2006-04-15
EP1662003A3 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
DK1334174T3 (da) Paramyxovirusvektor til genoverförsel til det cardiovaskulære system
PL346212A1 (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
CA2185712A1 (en) Enhanced virus-mediated dna transfer
ATE233084T1 (de) Pharmazeutische aerosolformulierung
DE69333529D1 (de) Pflanzenvirus-vektor, plasmid, methode der expression fremder gene und methode zur gewinnung obiger genprodukte
ID29968A (id) Urutan nukleotida untuk gen tal
ATE422534T1 (de) Verfahren zum trocknen von mikroorganismen
ITRM980716A1 (it) Atomizzatore rotativo per applicare rivestimenti su oggetti, fornito di un sistema ad aria per la distribuzione del getto.
Schlesinger et al. Mechanisms involved in natural and experimental neuropathogenicity of influenza viruses: evidence and speculation
NO995697D0 (no) Gen-vektorer
HRP20050424A2 (en) Process for making risperidone and intermediates thereof
DE50110723D1 (de) Isolierte luziferasen sowie deren verwendung
MX9702316A (es) Procesos para la preparacion del acido ciclopropancarboxilico y sus derivados.
BR0002150A (pt) Crescimento melhorado de bactérias de ácido láctico em leite
WO2003029274A3 (en) Paramyxoviruses as gene transfer vectors to lung cells
WO2002002766A3 (en) Natural promoters for gene expression and metabolic monitoring in bacillus species
WO2007125445A3 (en) An array of swim care articles and method for providing same to shopper and retailer
ATE428793T1 (de) Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
WO2001094588A3 (en) Gene (cur) related to a curly phenotype in plants
EP1030867A4 (en) MAMMAL MILK GROWTH FACTOR
BR0003561A (pt) Processo para a preparação fermentativa de produtos metabólicos e para as sequências de nucleotìdeos codificando para o gene sod
ATE400583T1 (de) Neues gen, welches bei der krankheit apeced defekt ist, und dessen verwendungen
HK1043155A1 (zh) 噬菌體t4基因35的基因及蛋白質排列
DK1029063T3 (da) Ikke-RCR leuconostoc-plasmid, der kan overföres til mælkesyrebakterier, anvendelse som klonings- og ekspressionsredskab
IT1320168B1 (it) Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide.